{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:14:39Z","timestamp":1789564479776,"version":"build-2803163510"},"reference-count":8,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.kint.2025.11.004","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:40:59Z","timestamp":1764056459000},"page":"283-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Equity in evidence: overcoming barriers to kidney trials in low-resource settings"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1562-9912","authenticated-orcid":false,"given":"Soumita","family":"Bagchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germaine","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.11.004_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/j.ajkd.2024.06.012","article-title":"Representation of low- and middle-income countries in CKD drug trials: a systematic review","volume":"85","author":"Cojuc-Konigsberg","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.11.004_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrneph.2015.6","article-title":"Access to medications and conducting clinical trials in LMICs","volume":"11","author":"Okpechi","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2025.11.004_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12939-018-0748-6","article-title":"Barriers for conducting clinical trials in developing countries\u2014a systematic review","volume":"17","author":"Alemayehu","year":"2018","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.kint.2025.11.004_bib4","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.ekir.2023.09.034","article-title":"Clinical practice patterns in IgA nephropathy: a global questionnaire-based survey","volume":"8","author":"Bansal","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.11.004_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6905","article-title":"Effects of socioeconomic status on enrollment in clinical trials for cancer: a systematic review","volume":"13","author":"Donzo","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.kint.2025.11.004_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijmyco.2016.02.005","article-title":"The pros and cons of the QuantiFERON test for the diagnosis of tuberculosis, prediction of disease progression, and treatment monitoring","volume":"5","author":"Ndzi","year":"2016","journal-title":"Int J Mycobacteriol"},{"key":"10.1016\/j.kint.2025.11.004_bib7","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.kint.2024.11.007","article-title":"KDIGO 2025 clinical practice guideline for the management of nephrotic syndrome in children","volume":"107","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Nephrotic Syndrome in Children Work Group","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.11.004_bib8","article-title":"Drug development in LMICs: could the emerging Indian model usher the southeast Asian region?","volume":"29","author":"Pant","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:04:24Z","timestamp":1781456664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825008890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0085253825008890"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.11.004","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Equity in evidence: overcoming barriers to kidney trials in low-resource settings","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}